Press Releases | Viatris https://newsroom.viatris.com/ Newsroom Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia https://newsroom.viatris.com/2026-10-16-Viatris-Receives-U-S-FDA-Approval-for-RYZUMVI-R-for-the-Treatment-of-Presbyopia Fri, 16 Oct 2026 16:05:00 -0400 https://newsroom.viatris.com/2026-10-16-Viatris-Receives-U-S-FDA-Approval-for-RYZUMVI-R-for-the-Treatment-of-Presbyopia Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies https://newsroom.viatris.com/2026-10-08-Viatris-Agrees-to-Acquire-Pacira-BioSciences,-Advancing-Its-Innovative-Medicines-Strategy-and-Becoming-a-Leader-in-Non-Opioid-Pain-Therapies Thu, 08 Oct 2026 07:45:00 -0400 https://newsroom.viatris.com/2026-10-08-Viatris-Agrees-to-Acquire-Pacira-BioSciences,-Advancing-Its-Innovative-Medicines-Strategy-and-Becoming-a-Leader-in-Non-Opioid-Pain-Therapies Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026 https://newsroom.viatris.com/2026-10-05-Viatris-to-Report-Third-Quarter-2026-Financial-Results-on-November-5,-2026 Mon, 05 Oct 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-10-05-Viatris-to-Report-Third-Quarter-2026-Financial-Results-on-November-5,-2026 Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year https://newsroom.viatris.com/2026-09-29-Viatris-Recognized-by-Forbes-as-One-of-the-Worlds-Best-Employers-for-the-Sixth-Consecutive-Year Tue, 29 Sep 2026 14:00:00 -0400 https://newsroom.viatris.com/2026-09-29-Viatris-Recognized-by-Forbes-as-One-of-the-Worlds-Best-Employers-for-the-Sixth-Consecutive-Year Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome https://newsroom.viatris.com/2026-09-16-Viatris-Announces-Approval-of-WAKIX-R-Pitolisant-in-Japan,-a-First-in-Class-Treatment-for-Narcolepsy-and-Excessive-Daytime-Sleepiness-Associated-With-Obstructive-Sleep-Apnea-Syndrome Wed, 16 Sep 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-09-16-Viatris-Announces-Approval-of-WAKIX-R-Pitolisant-in-Japan,-a-First-in-Class-Treatment-for-Narcolepsy-and-Excessive-Daytime-Sleepiness-Associated-With-Obstructive-Sleep-Apnea-Syndrome Viatris Reports Second-Quarter 2026 Financial Results https://newsroom.viatris.com/2026-08-06-Viatris-Reports-Second-Quarter-2026-Financial-Results Thu, 06 Aug 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-08-06-Viatris-Reports-Second-Quarter-2026-Financial-Results Viatris Announces Quarterly Dividend https://newsroom.viatris.com/2026-08-04-Viatris-Announces-Quarterly-Dividend Tue, 04 Aug 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-08-04-Viatris-Announces-Quarterly-Dividend Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch https://newsroom.viatris.com/2026-07-29-Viatris-Receives-U-S-FDA-Approval-for-Gwyn-Lo-TM-,-a-Once-Weekly-Contraceptive-Patch Wed, 29 Jul 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-07-29-Viatris-Receives-U-S-FDA-Approval-for-Gwyn-Lo-TM-,-a-Once-Weekly-Contraceptive-Patch Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 https://newsroom.viatris.com/2026-07-01-Viatris-to-Report-Second-Quarter-2026-Financial-Results-on-August-6,-2026 Wed, 01 Jul 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-07-01-Viatris-to-Report-Second-Quarter-2026-Financial-Results-on-August-6,-2026 Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy https://newsroom.viatris.com/2026-06-29-Viatris-Announces-Positive-Top-Line-Results-from-Phase-3-Study-of-VR-205-in-Japanese-Adults-with-Primary-Immunoglobulin-A-Nephropathy Mon, 29 Jun 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-06-29-Viatris-Announces-Positive-Top-Line-Results-from-Phase-3-Study-of-VR-205-in-Japanese-Adults-with-Primary-Immunoglobulin-A-Nephropathy U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain https://newsroom.viatris.com/2026-05-18-U-S-FDA-Accepts-Viatris-New-Drug-Application-for-Fast-Acting-Meloxicam-for-the-Treatment-of-Moderate-to-Severe-Acute-Pain Mon, 18 May 2026 08:00:00 -0400 https://newsroom.viatris.com/2026-05-18-U-S-FDA-Accepts-Viatris-New-Drug-Application-for-Fast-Acting-Meloxicam-for-the-Treatment-of-Moderate-to-Severe-Acute-Pain Viatris to Present at the Bank of America Securities 2026 Healthcare Conference https://newsroom.viatris.com/2026-05-07-Viatris-to-Present-at-the-Bank-of-America-Securities-2026-Healthcare-Conference Thu, 07 May 2026 16:30:00 -0400 https://newsroom.viatris.com/2026-05-07-Viatris-to-Present-at-the-Bank-of-America-Securities-2026-Healthcare-Conference Viatris Reports First-Quarter 2026 Financial Results https://newsroom.viatris.com/2026-05-07-Viatris-Reports-First-Quarter-2026-Financial-Results Thu, 07 May 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-05-07-Viatris-Reports-First-Quarter-2026-Financial-Results Viatris Announces Quarterly Dividend https://newsroom.viatris.com/2026-05-05-Viatris-Announces-Quarterly-Dividend Tue, 05 May 2026 06:59:00 -0400 https://newsroom.viatris.com/2026-05-05-Viatris-Announces-Quarterly-Dividend Viatris Announces Chief Financial Officer Transition https://newsroom.viatris.com/2026-05-04-Viatris-Announces-Chief-Financial-Officer-Transition Mon, 04 May 2026 16:30:00 -0400 https://newsroom.viatris.com/2026-05-04-Viatris-Announces-Chief-Financial-Officer-Transition